Retatrutide vs liraglutide · receptor comparison · research use only
Retatrutide vs liraglutide — triple-agonist versus first-generation GLP-1.
Liraglutide was the compound that established the clinical credibility of GLP-1 receptor agonism for metabolic research — FDA-approved as Victoza for type 2 diabetes in 2010 and as Saxenda for obesity in 2014, it was the first GLP-1 agent to earn an obesity indication and defined the benchmark that all subsequent incretin compounds are measured against. Retatrutide is the furthest extension of that receptor-targeting logic: a triple GIP/GLP-1/glucagon receptor agonist now in Phase 3 trials with TRIUMPH-1 results showing up to 30% mean weight loss at 104 weeks — roughly twice the weight reduction observed in the SCALE trial for liraglutide (~13%). This comparison is a research-context reference, not clinical guidance. Titan Peptide Lab supplies retatrutide as a research-use-only compound and does not stock liraglutide; neither is positioned here as a clinical recommendation, substitute, or alternative for any prescribed treatment.
Receptor targeting: single GLP-1 vs triple GIP/GLP-1/glucagon
The core pharmacological distinction: liraglutide targets a single receptor (GLP-1R) with high selectivity — that is the entirety of its incretin receptor profile. Retatrutide targets three receptors simultaneously: GIP receptor (~8.9× relative potency), GLP-1 receptor (~0.4× relative potency), and glucagon receptor (~0.3× relative potency). Adding GIP receptor agonism is the tirzepatide innovation (dual agonist); retatrutide adds the glucagon receptor as a third arm on top of that. Each additional receptor arm is studied for incremental metabolic effects — GIP for insulin potentiation and adipogenesis, glucagon for thermogenesis and energy expenditure.
Retatrutide mechanism in detail →Clinical trial weight-loss data: SCALE vs TRIUMPH
The SCALE obesity trial (Pi-Sunyer et al. NEJM 2015;373:11-22, PMID 26132939) is the pivotal Phase 3 liraglutide 3mg trial — 3,731 adults with obesity, 56 weeks, achieving a mean −8.4 kg (approximately −8–9% body weight) versus −2.8 kg placebo, with approximately 63% of participants achieving ≥5% weight loss. The TRIUMPH-1 retatrutide Phase 3 trial (n=2,339, 104 weeks, published May 21, 2026) reported up to 30% mean weight reduction at the highest doses. The comparison is not head-to-head and the populations and durations differ, but the approximate doubling of magnitude across successive generations of incretin agents — liraglutide (~8–13%), semaglutide (~15–17%), tirzepatide (~20–22%), retatrutide (~25–30%) — reflects the receptor-targeting progression.
TRIUMPH Phase 3 data →Half-life and dosing interval
Liraglutide has a plasma half-life of approximately 13 hours, which is why it is dosed once daily — a characteristic that drove Novo Nordisk's subsequent development of semaglutide (~7-day half-life, weekly dosing). Retatrutide achieves its approximately 6-day half-life through a fatty diacid (C20) acylation strategy — the same approach as semaglutide but with a longer chain modification that also contributes to the multi-receptor pharmacology. For research purposes: liraglutide is a first-generation acylated GLP-1 analogue with daily dosing; retatrutide is a third-generation fatty diacid-modified triple agonist with weekly dosing.
Retatrutide half-life reference →Safety profile differences
Both compounds share the GLP-1 receptor agonism nausea/vomiting/GI adverse-event profile typical of the class. Retatrutide's glucagon receptor arm introduces a safety consideration not present with liraglutide: a dose-dependent heart rate elevation (tachycardia signal) that was observed in Phase 2 data and is being monitored in the TRIUMPH trials. This distinguishes retatrutide from both liraglutide and tirzepatide and is a key pharmacological difference for research design. The GLP-1 GI effects are similar across agents; the cardiovascular monitoring requirement differs.
GLP-1 regulatory context 2026 →Approval status: FDA-approved vs investigational
Liraglutide (Victoza for T2D, Saxenda for obesity) is FDA-approved and can be prescribed by licensed physicians for its approved indications. Retatrutide is investigational — as of July 2026, Phase 3 trials are complete or ongoing and no NDA has been publicly filed. Titan does not sell liraglutide in any format; Titan supplies retatrutide as a research-use-only compound for in-vitro laboratory research. These are entirely separate supply channels: the clinical/prescription channel for liraglutide versus the RUO research supply channel for retatrutide.
Where to get retatrutide research vial →Why researchers compare them
The cross-search between retatrutide and liraglutide is a generational-benchmark comparison: liraglutide established the first obesity-indication GLP-1 standard, and retatrutide represents the most advanced incretin receptor-targeting approach currently in late-stage trials. Researchers designing metabolic study protocols, modeling incretin receptor contributions, or reviewing the generation-by-generation pharmacology of this drug class use this comparison to contextualize the mechanistic evolution — not to identify a clinical substitution. Titan documents this comparison in research-use framing only.
Retatrutide vs semaglutide →The detail, in plain terms
Retatrutide vs liraglutide — side-by-side.
Research-use comparison. All data from peer-reviewed publications or Eli Lilly/Novo Nordisk Phase 3 announcements. Retatrutide: investigational. Liraglutide: FDA-approved — Titan does not stock it.
- Mechanism
- Retatrutide: triple GIP/GLP-1/GcgR agonist. Liraglutide: single GLP-1R agonist only.
- GIP receptor
- Retatrutide: YES (~8.9× potency). Liraglutide: NO — GLP-1R only.
- Glucagon receptor
- Retatrutide: YES (~0.3× potency; thermogenesis/energy expenditure). Liraglutide: NO.
- Half-life / dosing
- Retatrutide: ~6 days; weekly dosing (C20 fatty diacid). Liraglutide: ~13 hours; once-daily dosing (C18 fatty acid).
- Phase 3 weight loss
- Retatrutide: TRIUMPH-1 up to ~30% at 104wk (2026). Liraglutide: SCALE ~8–13% at 56wk (Pi-Sunyer NEJM 2015).
- Heart rate signal
- Retatrutide: dose-dependent HR elevation (glucagon arm). Liraglutide: modest HR increase, less pronounced than retatrutide.
- FDA status
- Retatrutide: investigational / Breakthrough Therapy Designation / NDA not filed (Jul 2026). Liraglutide: FDA-approved 2010 (T2D) / 2014 (obesity).
- Titan supply
- Retatrutide: lyophilized research vial, RUO, $199.99. Liraglutide: NOT stocked by Titan.
head-to-head
Retatrutide vs liraglutide — receptor and trial data
Mechanism and efficacy context from published Phase 3 data. Research use only.
| Criterion | Retatrutide | Liraglutide |
|---|---|---|
| Receptor target(s) | GIP + GLP-1 + Glucagon (triple) | GLP-1 only (single) |
| Generation | Third-generation incretin (investigational) | First-generation GLP-1 agonist (approved) |
| Half-life | ~6 days (weekly) | ~13 hours (daily) |
| Phase 3 weight loss | ~25–30% at 104wk (TRIUMPH-1 2026) | ~8–13% at 56wk (SCALE 2015) |
| Heart rate effect | Dose-dependent elevation (glucagon arm) | Modest increase |
| FDA approval | Investigational — no NDA filed (Jul 2026) | Approved: Victoza (T2D 2010), Saxenda (obesity 2014) |
| Titan RUO stock | Yes — lyophilized vial $199.99 | No — not stocked |
Questions researchers ask
Before you order.
- How does retatrutide compare to liraglutide?
- The fundamental difference is receptor targeting: liraglutide is a single GLP-1 receptor agonist, while retatrutide adds GIP and glucagon receptor agonism for a triple-receptor mechanism. In Phase 3 trial data, this translates to substantially greater weight-loss efficacy: liraglutide achieved approximately 8–13% mean weight reduction at 56 weeks in the SCALE trial, while retatrutide reached approximately 25–30% at 104 weeks in TRIUMPH-1. They are in different drug generations and different regulatory stages — liraglutide is FDA-approved, retatrutide is investigational as of July 2026.
- Is retatrutide stronger than liraglutide?
- In terms of weight-reduction efficacy data, the Phase 3 evidence suggests yes — TRIUMPH-1 results (~30% at highest dose, 104 weeks) substantially exceed SCALE results for liraglutide (~13% at 56 weeks). The two comparisons are not head-to-head, involve different populations and durations, and the mechanisms differ. The generational progression across incretin agents — liraglutide → semaglutide → tirzepatide → retatrutide — shows a consistent step-up in weight-loss efficacy that maps to the expansion of receptor targeting. Research comparison only; neither is evaluated for clinical superiority here.
- What is the half-life difference between retatrutide and liraglutide?
- Liraglutide has a half-life of approximately 13 hours, requiring once-daily dosing. It is acylated with a C18 fatty acid. Retatrutide has a half-life of approximately 6 days, enabling once-weekly dosing. It uses a C20 fatty diacid acylation strategy — a longer acyl chain that extends the half-life and contributes to its multi-receptor pharmacology. The shift from daily to weekly dosing is a major practical difference in research study design for in-vivo models.
- Does Titan sell liraglutide?
- No. Titan Peptide Lab does not stock liraglutide. Titan supplies retatrutide as a lyophilized research-use-only vial ($199.99) for in-vitro and pre-clinical laboratory research. Liraglutide is an FDA-approved prescription medication available through licensed pharmacies and prescribers — an entirely separate channel from the RUO research supply space.
- Can retatrutide replace liraglutide in research?
- They are distinct compounds with different receptor profiles and different pharmacokinetics — not interchangeable in research design. A study designed to study GLP-1 receptor agonism in isolation cannot substitute retatrutide (which also activates GIP and glucagon receptors) for liraglutide without confounding the results. The correct choice depends entirely on the research question: GLP-1-specific pathway study → liraglutide; triple-receptor GIP/GLP-1/glucagon study → retatrutide. Research use only.
Related reading